Psychiatry

Views & Analysis

Social psychology concept as a group of connected network of people icons with one individual brain illuminated as a symbol for sociology and group interaction.

Predicting and improving clinical trial enrolment: A problem...

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a tri

News

Sage/Biogen's zuranolone works in depression, but maybe not ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial po

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Aduhelm approval could signal new era for CNS drugs; analyst...

The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a

News

Study finds "alarming" hike in antidepressant costs during C...

Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs.

News

After FDA approval, Alkermes plans soft launch for antipsych...

The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ge

News

Great Britain £50 - fifty pounds sterling notes spead out.

Tribunal maintains Lexon’s £1.2m fine for breaking competiti...

Pharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused it of exchanging commercially sensitive information about prices for nortriptylin

Predicting and improving clinical trial enrolment: A problem...

Sage/Biogen's zuranolone works in depression, but maybe not ...

Aduhelm approval could signal new era for CNS drugs; analyst...

Study finds "alarming" hike in antidepressant costs during C...

After FDA approval, Alkermes plans soft launch for antipsych...

Tribunal maintains Lexon’s £1.2m fine for breaking competiti...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Psychiatry

Editor's Picks